Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MGTA-456 in Patients With High-Risk Malignancy
NCT03674411Phase 2Active, not recruiting
- Sponsor
- Masonic Cancer Center
- Start
- Jan 2019
- Primary completion
- Jun 2020
- Modality
- Hematopoietic Stem Cells
- Countries
- 1
01
Overview
A Phase 2 trial of spanlecortemlocel in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), mixed phenotype acute leukemia (MPAL), acute undifferentiated leukemia (AUL), chronic myelogenous leukemia (CML), sponsored by Masonic Cancer Center. Started Jan 2019; status: active, not recruiting.
02
Drugs
spanlecortemlocel
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)mixed phenotype acute leukemia (MPAL)acute undifferentiated leukemia (AUL)chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT03674411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03674411.